scispace - formally typeset
Z

Zrinka Jajić

Researcher at University of Zagreb

Publications -  72
Citations -  1932

Zrinka Jajić is an academic researcher from University of Zagreb. The author has contributed to research in topics: Ankylosing spondylitis & Dermatoglyphics. The author has an hindex of 12, co-authored 72 publications receiving 1692 citations.

Papers
More filters
Journal ArticleDOI

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials

TL;DR: Although NSAIDs increase vascular and gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making.
Journal ArticleDOI

Primary hypertrophic osteoarthropathy: clinical, radiologic, and scintigraphic characteristics.

TL;DR: PHO has special clinical and radiographic manifestations (finger clubbing and periostosis of the long bones) that are associated with some minor manifestations and requires a special diagnostic assessment.
Journal ArticleDOI

Peripheral Blood Expression Profiles of Bone Morphogenetic Proteins, Tumor Necrosis Factor-superfamily Molecules, and Transcription Factor Runx2 Could Be Used as Markers of the Form of Arthritis, Disease Activity, and Therapeutic Responsiveness

TL;DR: BMP and Runx2 were identified as possible biomarkers of bone metabolism in several forms of arthritis, while lower FasL and LIGHT were associated with RA and methotrexate-treated patients in RA, respectively.
Journal ArticleDOI

Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.

TL;DR: Novel insights into migratory behaviors and functional properties of circulatory OCPs in response to chemotactic signals could open ways to new therapeutic targets in RA.
Journal ArticleDOI

Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis

TL;DR: Positive association between the proportion of peripheral blood OCPs, defined as CD3−CD19−CD56−CD11b+CD14+, and the disease activity score in the follow-up samples from patients with psoriatic arthritis receiving anti-TNF therapy is confirmed.